Overview

Neoadjuvant Nivolumab in Glioblastoma

Status:
Completed

Trial end date:
2017-03-01

Target enrollment:

Participant gender:

Summary

Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.

Phase:

Phase 2

Details

Lead Sponsor:

Clinica Universidad de Navarra, Universidad de Navarra

Treatments:

Antibodies, Monoclonal
Nivolumab